The search for responsive clinical endpoints in primary progressive multiple sclerosis

Abstract

Objective

To determine whether in primary progressive multiple sclerosis (PPMS) combining scores of Expanded Disability Status Scale (EDSS) with data from Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9HPT) would produce a clinical endpoint that has a higher event rate than EDSS alone.

Methods

In a group of 161 PPMS patients, EDSS, T25FW, and 9HPT were performed at three time points over 2 years. We calculated how many patients showed clinically meaningful deterioration (or improvement) on individual and combined scales. We defined improvements on one scale with deterioration on the other as “opposing changes.” We investigated the possible effect of baseline disability on the definition of our endpoint by dividing the population into two subsets of patients determined by baseline EDSS level.

Results

On individual scales, event rates were highest on T25FW: 34% and 46% 1 year and 2 years after baseline. On a combination of two scales, at 1 year the event rate was highest on T25FW/9HPT (46%; with a high rate of opposing changes) and at 2 years on T25FW/EDSS (57%; with a lower rate of opposing changes). In both subsets, event rates were highest on T25FW and (at 2 years) on the combination of T25FW/EDSS.

Conclusions

T25FW has the highest event rate as a single scale, independent of baseline disability level. A term of 2 years turned out to be more meaningful to observe than 1 year. “Worsening on either T25FW or EDSS” is the most appropriate composite endpoint in this patient group.

Keywords

9HPT clinical trials EDSS multiple sclerosis outcome measurement primary progressive T25FW

Get full access to this article

View all access options for this article.

References

1 Revesz T Kidd D Thompson AJ Barnard RO McDonald WI . A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117(pt 4): 759–765.

2 Thompson AJ Kermode AG MacManus DG . Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990; 300: 631–634.

3 Thompson AJ Kermode AG Wicks D . Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53–62.

4 Leary SM Miller DH Stevenson VL Brex PA Chard DT Thompson AJ . Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44–51.

5 Montalban X . Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004; 10(Suppl. 1): S62–S64.

6 Wolinsky JS Narayana PA O’Connor P . Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.

7 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

8 Lublin FD Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–911.

9 Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

10.

10 Cutter GR Baier ML Rudick RA . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(pt 5): 871–882.

11.

11 Schwid SR Goodman AD McDermott MP Bever CF Cook SD . Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58: 1294–1296.

12.

12 Hoogervorst EL Kalkers NF Cutter GR Uitdehaag BM Polman CH . The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 55–60.

13.

13 Kragt JJ van der Linden FA Nielsen JM Uitdehaag BM Polman CH . Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006; 12: 594–598.

14.

14 Goodkin DE; . EDSS reliability. Neurology 1991; 41(2 (Pt 1)): 332.

15.

15 Cottrell DA Kremenchutzky M Rice GP Hader W Baskerville J Ebers GC . The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999; 122(pt 4): 641–647.

16.

16 Cottrell DA Kremenchutzky M Rice GP . The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122(pt 4): 625–639.

17.

17 Ingle GT Stevenson VL Miller DH Thompson AJ . Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003; 126(pt 11): 2528–2536.

18.

18 Kragt JJ Thompson AJ Montalban X . Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008; 70: 1084–1091.

19.

19 Hobart JC Riazi A Lamping DL Fitzpatrick R Thompson AJ . Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003; 60: 31–36.